Key result
An 8-week treatment with a fixed-dose combination of amlodipine and valsartan normalized blood pressure in 85.2% of patients on the 10/ dose and 78.4% on the 5/ dose.
Why the study?
Does a fixed-dose combination of amlodipine and valsartan improve blood pressure control in hypertensive patients?
RCT (n=748)
randomized
Does a fixed-dose combination of amlodipine and valsartan improve blood pressure control in hypertensive patients?
A fixed-dose combination of amlodipine and valsartan provides highly effective blood pressure control while mitigating amlodipine-induced peripheral edema.
Answers are grounded in this paper and cite their sources.
May support BP control with amlodipine-valsartan combinations; leaves open need for randomized confirmation.
Pharmacological treatment of hypertension is effective in preventing cardiovascular and renal complications. Calcium antagonists and blockers of the renin-angiotensin system are widely used today to initiate antihypertensive therapy but, when given as monotherapy, do not suffice in most patients to normalize blood pressure. Combining the two types of agents considerably increases the antihypertensive efficacy, but not at the expense of a deterioration of tolerability. This is exemplified by the experience accumulated with the recently developed fixed dose combination containing the AT(1)-receptor blocker valsartan (160 mg) and the dihydropyridine amlodipine (5 or 10 mg). In a randomized trial, an 8-week treatment normalized blood pressure (<140/90 mmHg) within 8 weeks in a large fraction of hypertensive patients (78.4% and 85.2% using the 5/160 [n = 371] and 10/160 mg [n = 377] dosage, respectively). Like all AT(1)-receptor blockers valsartan has a placebo-like tolerability. Valsartan prevents to a large extent the occurrence amlodipine-induced peripheral edema. Both amlodipine and valsartan have beneficial effects on cardiovascular morbidity and mortality, as well as protective effects on renal function. The co-administration of these two agents is therefore very attractive, as it enables a rapid and sustained blood pressure control in hypertensive patients. The availability of a fixed-dose combination based on amlodipine and valsartan is expected therefore to facilitate the management of hypertension, to improve long-term adherence with antihypertensive therapy and, ultimately, to have a positive impact on cardiovascular and renal outcomes.
No takes yet. Share an insight, caveat, or question.
Bernard Waeber (2009) conducted an RCT in hypertension (n=748). Amlodipine and valsartan fixed-dose combination vs. Amlodipine and valsartan 5/160 mg was evaluated on Normalized blood pressure (<140/90 mmHg). An 8-week treatment with a fixed-dose combination of amlodipine and valsartan normalized blood pressure in 85.2% of patients on the 10/ dose and 78.4% on the 5/ dose.
Synapse has enriched 10 related papers. Consider them for comparative context: